Please Wait
Applying Filters...
menu
    • menu
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    Lee Pharma Ltd: Global supplier of certified APIs and formulations, driven by innovation and regulatory excellence.

    Virtual Booth

    Contact Supplier

    Farmak works in the development, production and marketing of APIs, Intermediates & Specialties// FDA inspected.

    Virtual Booth

    Contact Supplier

    Ethypharm is an international Pharma company with European roots manufacturing and commercializing essential drugs all over the world.

    Virtual Booth

    Contact Supplier

    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    Menu

    Lanadelumab

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Filters Filter
    Cross PopUp
    FILTER :

    filter clear-filterReset all filters

    01 4Gowling WLG (Canada) LLP

    filter clear-filterReset all filters

    filter clear-filterReset all filters

    filter clear-filterReset all filters

    filter clear-filterReset all filters

    PharmaCompass
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    01

    Gowling WLG (Canada) LLP

    LANADELUMAB
    arrow
    ESCRS
    Not Confirmed

    Gowling WLG (Canada) LLP

    Country
    arrow
    ESCRS
    Not Confirmed

    Patent Expiration Date : 2031-01-06

    Date Granted : 2018-12-18

    LANADELUMAB

    Brand Name : TAKHZYRO

    Patent Number : 2786019

    Filing Date : 2011-01-06

    Strength per Unit : 300 mg / 2 mL

    Dosage Form : SOLUTION

    Human Or VET : Human

    Route of Administration : SUBCUTANEOUS

    Patent Expiration Date : 2031-01-06

    Date Granted : 2018-12-18

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Gowling WLG (Canada) LLP

    LANADELUMAB
    arrow
    ESCRS
    Not Confirmed

    Gowling WLG (Canada) LLP

    Country
    arrow
    ESCRS
    Not Confirmed

    Patent Expiration Date : 2031-01-06

    Date Granted : 2018-12-18

    LANADELUMAB

    Brand Name : TAKHZYRO

    Patent Number : 2786019

    Filing Date : 2011-01-06

    Strength per Unit : 300 mg / 2 mL

    Dosage Form : SOLUTION

    Human Or VET : Human

    Route of Administration : SUBCUTANEOUS

    Patent Expiration Date : 2031-01-06

    Date Granted : 2018-12-18

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Gowling WLG (Canada) LLP

    LANADELUMAB
    arrow
    ESCRS
    Not Confirmed

    Gowling WLG (Canada) LLP

    Country
    arrow
    ESCRS
    Not Confirmed

    Patent Expiration Date : 2035-01-21

    Date Granted : 2022-05-31

    LANADELUMAB

    Brand Name : TAKHZYRO

    Patent Number : 2937329

    Filing Date : 2015-01-21

    Strength per Unit : 300 mg / 2 mL

    Dosage Form : SOLUTION

    Human Or VET : Human

    Route of Administration : SUBCUTANEOUS

    Patent Expiration Date : 2035-01-21

    Date Granted : 2022-05-31

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Gowling WLG (Canada) LLP

    LANADELUMAB
    arrow
    ESCRS
    Not Confirmed

    Gowling WLG (Canada) LLP

    Country
    arrow
    ESCRS
    Not Confirmed

    Patent Expiration Date : 2035-01-21

    Date Granted : 2022-05-31

    LANADELUMAB

    Brand Name : TAKHZYRO

    Patent Number : 2937329

    Filing Date : 2015-01-21

    Strength per Unit : 300 mg / 2 mL

    Dosage Form : SOLUTION

    Human Or VET : Human

    Route of Administration : SUBCUTANEOUS

    Patent Expiration Date : 2035-01-21

    Date Granted : 2022-05-31

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF